Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST PHARMAC Form 4 May 22, 2015	EUTICALS I	INC							
FORM /							PPROVAL		
UNII	TED STATES	S SECURITIES A Washington			COMMISSIO	N OMB Number:	3235-0287		
Check this box if no longer									
subject to STA Section 16. Form 4 or	TEMENT O	F CHANGES IN SECUI	BENEF	Estimated burden hor response	urs per				
abligations	n 17(a) of the	Section 16(a) of the Public Utility Hol of the Investment	ding Cor	npany Act	of 1935 or Section				
(Print or Type Responses)									
1. Name and Address of Repo LEE KENNETH B JR	2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer					
		BIOCRYST PH INC [BCRX]	ARMAC	EUTICAL	(Check all applicable)				
(Last) (First)	· · · · · · · · · · · · · · · · · · ·			X_ Director 10% Owner Officer (give title Other (specify					
(Month/Day/Year) 4505 EMPEROR BLVD., SUITE 05/20/2015 200					below)	below)	ler (opeen)		
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				1	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
DURHAM, NC 27703					Person		aporting		
(City) (State)	(Zip)	Table I - Non-	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	Date 2A. Deem fear) Execution any (Month/D	Date, if Transactic Code ay/Year) (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
		Code V	Amount	(D) Price					
Reminder: Report on a separat	te line for each cl	lass of securities bene	Perso inforn requir	ns who rest nation cont red to responses a current	or indirectly. pond to the colle ained in this form and unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
		vative Securities Acc puts, calls, warrants				1			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amoun
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	ionDerivative	Expiration Date	Underlying Securiti

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8))	Securities Acquired (A or Disposed (D) (Instr. 3, 4, and 5)	red (A) posed of 3, 4,		(Instr. 3 and 4)		
				Code N	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou or Numl of Sh
Automatic Stock Option Grant (1)	\$ 11.39	05/20/2015		А		15,000		06/20/2015 <u>(2)</u>	05/20/2025	Common Stock	15,0

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
LEE KENNETH B JR 4505 EMPEROR BLVD., SUITE 200 DURHAM, NC 27703	Х			
Signatures				
/s/ Alane P. Barnes, by power of attorney	0	5/22/2015		
**Signature of Reporting Person		Date		
Explanation of Respon	10001			

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.

(2) Vests 1/12th per month over twelve months beginning June 20, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.